Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

14.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.2K
Vaccinations01:51

Vaccinations

44.2K
Overview
44.2K
Cross-reactivity00:42

Cross-reactivity

31.0K
Overview
31.0K
Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

543
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
543
Cancer Vaccines01:30

Cancer Vaccines

347
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
347
Development of Immunocompetence01:22

Development of Immunocompetence

295
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
295

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Why Is Mumps Vaccine not Persistently Effective?

The Pediatric infectious disease journal·2026
Same author

Chikungunya: Unpronounceable, But Important.

The Pediatric infectious disease journal·2026
Same author

Smallpox Is Gone, but Not Forgotten.

The Pediatric infectious disease journal·2026
Same author

Evidence for the Effectiveness of COVID-19 Vaccine in Children.

The Pediatric infectious disease journal·2026
Same author

The Future of RSV Disease Control.

The Pediatric infectious disease journal·2026
Same author

Are Antibodies Sufficient For Protection Against SARS-CoV-2 Infections?

The Pediatric infectious disease journal·2025

Related Experiment Video

Updated: Jun 14, 2025

Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells
12:54

Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells

Published on: May 19, 2023

1.8K

Vaccine Development Should Be Polytheistic, Not Monotheistic.

Stanley A Plotkin1, James M Robinson2, Joseph R A Fitchett3

  • 1University of Pennsylvania and Vaxconsult, Doylestown, Pennsylvania, USA.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|September 6, 2024
PubMed
Summary
This summary is machine-generated.

Messenger RNA (mRNA) vaccines are effective, but focusing solely on this technology may overlook older methods offering broader, longer-lasting protection against various pathogens.

Keywords:
immune responseslive-attenuated vaccinesmRNA technologyvaccine developmentvaccine platforms

More Related Videos

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.2K
Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes
08:27

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes

Published on: August 13, 2021

4.4K

Related Experiment Videos

Last Updated: Jun 14, 2025

Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells
12:54

Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells

Published on: May 19, 2023

1.8K
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.2K
Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes
08:27

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes

Published on: August 13, 2021

4.4K

Area of Science:

  • Vaccinology
  • Immunology
  • Biotechnology

Background:

  • Messenger RNA (mRNA) vaccine technology has demonstrated significant success.
  • However, mRNA vaccines may not possess optimal characteristics for all infectious agents.

Purpose of the Study:

  • To evaluate the potential limitations of an exclusive focus on mRNA vaccine technology.
  • To highlight the importance of considering alternative vaccine platforms for comprehensive pathogen protection.

Main Methods:

  • Comparative analysis of vaccine technologies.
  • Review of existing literature on vaccine efficacy and durability.

Main Results:

  • mRNA vaccines, while successful, may not be universally suitable for all pathogens.
  • Over-reliance on mRNA technology risks neglecting established platforms with proven broader and more persistent protective qualities.

Conclusions:

  • A balanced approach incorporating diverse vaccine technologies is crucial for robust public health strategies.
  • Exploring and maintaining older vaccine technologies alongside newer ones ensures preparedness against a wider spectrum of diseases.